Receptor Monoclonal Antibodies that Inhibit Tumor Angiogenesis
Annual rept. 1 Aug 1998-31 Jul 1999
ADIRONDACK BIOMEDICAL RESEARCH INST LAKE PLACID NY
Pagination or Media Count:
The purpose of this project is to generate monoclonal antibodies to receptor molecules for the angiogenic growth factor VEGF. These antibodies will be tested for their potential as inhibitors of VEGF-stimulated angiogenesis, which is thought to play an important role in the development of breast cancer. A number of hybridoma fusions have been done, but screening has been delayed. Research defining the VEGF binding site of the Fit-i receptor is in press this work will aid in the selection of receptor fragments for immunization. Research elucidating two signaling pathways required for VFGF-stimulated endothelial cell proliferation has been published a conclusion of that study is that therapeutic intervention of VEGF-induced angiogenesis should focus on early signaling events.
- Anatomy and Physiology
- Medicine and Medical Research